title: Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.
authors.forename: Manuel Jorge
authors.initials: MJ
authors.lastname: Rodrigues
authors.forename: Johanna
authors.initials: J
authors.lastname: Wassermann
authors.forename: Laurence
authors.initials: L
authors.lastname: Albiges
authors.forename: Etienne
authors.initials: E
authors.lastname: Brain
authors.forename: Suzette
authors.initials: S
authors.lastname: Delaloge
authors.forename: Denise
authors.initials: D
authors.lastname: Stevens
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Guinebretière
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Mathieu
authors.forename: Youlia
authors.initials: Y
authors.lastname: Kirova
authors.forename: Eugénie
authors.initials: E
authors.lastname: Guillot
authors.forename: Anne
authors.initials: A
authors.lastname: Vincent-Salomon
authors.forename: Paul H
authors.initials: PH
authors.lastname: Cottu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D005602:France; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012189:Retrospective Studies; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab